|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash Flows From Operating Activities | |||||
| Net loss | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization expense | |||||
| Bad debt expense (recovery) | |||||
| Bad debt recovery | |||||
| Equity based compensation expense - stock | |||||
| Equity based compensation expense - options | |||||
| Accounts receivable collected on assets held for distribution | |||||
| Allowance for (recovery of) credit losses | |||||
| Impairment expense | |||||
| Gain or loss on debt settlement | |||||
| Equity based compensation expense | |||||
| Warrant modification expense | |||||
| Loss on shares issued in settlement of consulting agreement | |||||
| Loss on debt settlement | |||||
| Gain on deconsolidation | |||||
| Change in fair value of derivative liability | |||||
| Change in fair value of warrant liability | |||||
| Loss on adjustment of fair value of marketable securities | |||||
| Gain on assets sale | |||||
| Change in fair value of earn-out liability | |||||
| Amortization of debt discount and debt costs | |||||
| Loss on loan amendment | |||||
| Factoring discount fee and interest | |||||
| Change in fair value of contingent consideration | |||||
| Changes in assets and liabilities: | |||||
| (Increase) decrease in accounts receivable | |||||
| Decrease in accounts receivable - related parties | |||||
| Investment in Marketable Securities | |||||
| Decrease (increase) in prepaid expenses and other current assets | |||||
| Increase (decrease) in accounts payable and accrued liabilities | |||||
| Decrease in accounts payable and accrued liabilities - related parties | |||||
| Deferred payroll taxes | |||||
| Decrease in deferred revenue | |||||
| Net cash used in operating activities | |||||
| Cash Flows from Investing Activities: | |||||
| Capitalized software development costs | |||||
| Proceeds from sale of intangible assets | |||||
| Purchase of property and equipment | |||||
| Purchase of intangible assets | |||||
| Proceeds from sale of assets | |||||
| Net cash (used in) provided by investing activities | |||||
| Cash Flows from Financing Activities: | |||||
| Proceeds from notes | |||||
| Issuance of common stock, net of fees | |||||
| Repayments of notes | |||||
| Gross proceeds from exercise of the warrants | |||||
| Proceeds from ERC advances | |||||
| Repayment of ERC advances | |||||
| Proceeds from factoring agreement | |||||
| Repayments of factoring agreement | |||||
| Purchase of preferred shares pursuant to recapitalization | |||||
| Proceeds from sale of common stock in offering | |||||
| Proceeds from line of credit payable | |||||
| Net cash provided by financing activities | |||||
| Net (decrease) increase in cash | |||||
| Cash, beginning of year | |||||
| Cash, end of year | |||||
| Supplemental disclosures of cash flow information: | |||||
| Cash paid during the year for interest | |||||
| Cash paid during the year for income taxes | |||||
| Purchase price measurement period adjustment to goodwill and accounts receivable | |||||
| Debt discount on warrants granted with notes | |||||
| Issuance of common stock issued upon purchase of intangible assets | |||||
| Warrants issued in connection with purchase of intangible assets | |||||
| Issuance of common stock issued upon conversion of note payable | |||||
| Issuance of common stock from conversion of Preferred stock, Series E | |||||
| Issuance of common stock from conversion of warrants | |||||
| Issuance of common stock for debt settlements | |||||
| Accounts receivable owed under factoring agreement collected directly by factor | |||||
| Deemed dividends | |||||
| Offering costs as a result of modification of warrants to induce exercise | |||||
| Financing of insurance premium | |||||
| Debt discount on loan amendment | |||||
| Transfer of accrued interest to loan principal upon loan amendment | |||||
| Supplemental schedule of non-cash investing and financing activities: | |||||
| Issuance of common stock issued upon purchase of intangible assets | |||||
| Warrants issued in connection with purchase of intangible assets | |||||
| Issuance of common stock issued upon conversion of note payable | |||||
| Issuance of common stock from conversion of warrants | |||||
| Issuance of common stock for debt settlements | |||||
| Stock to be issued for fixed consideration | |||||
| Issuance of common stock upon debt conversion | |||||
| D&O Insurance Policy | |||||
| Distribution associated with Spin-off | |||||
Loading...